메뉴 건너뛰기




Volumn 47, Issue 4, 2017, Pages 346-353

Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine

Author keywords

Antioxidant; inhibitor; n acetylcysteine; organic anion tranporter; pharmacokinetics; probenecid; transporter

Indexed keywords

ACETYLCYSTEINE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PROBENECID; ORGANIC ANION TRANSPORTER;

EID: 84973615743     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498254.2016.1187777     Document Type: Article
Times cited : (41)

References (37)
  • 3
    • 0345018815 scopus 로고    scopus 로고
    • N-acetylcysteine: pharmacological considerations and experimental and clinical applications
    • Cotgreave IA., (1997). N-acetylcysteine:pharmacological considerations and experimental and clinical applications. Adv Pharmacol 38:205–27
    • (1997) Adv Pharmacol , vol.38 , pp. 205-227
    • Cotgreave, I.A.1
  • 4
    • 57649148545 scopus 로고    scopus 로고
    • N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility
    • Dodd S, Dean O, Copolov DL, et al. (2008). N-acetylcysteine for antioxidant therapy:pharmacology and clinical utility. Expert Opin Biol Ther 8:1955–62
    • (2008) Expert Opin Biol Ther , vol.8 , pp. 1955-1962
    • Dodd, S.1    Dean, O.2    Copolov, D.L.3
  • 5
    • 84925699316 scopus 로고    scopus 로고
    • The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat
    • Donovan MD, O'brien FE, Boylan GB, et al. (2015). The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain:an integrated in vivo microdialysis study in the rat. J Pharm Pharmacol 67:501–10
    • (2015) J Pharm Pharmacol , vol.67 , pp. 501-510
    • Donovan, M.D.1    O'brien, F.E.2    Boylan, G.B.3
  • 6
    • 33645743694 scopus 로고    scopus 로고
    • The human organic anion transporter 3 (oat3; slc22a8): genetic variation and functional genomics
    • Erdman AR, Mangravite LM, Urban TJ, et al. (2006). The human organic anion transporter 3 (oat3; slc22a8):genetic variation and functional genomics. Am J Physiol Renal Physiol 290:F905–12
    • (2006) Am J Physiol Renal Physiol , vol.290 , pp. F905-F912
    • Erdman, A.R.1    Mangravite, L.M.2    Urban, T.J.3
  • 7
    • 84865651194 scopus 로고    scopus 로고
    • Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant n-acetylcysteine
    • Erickson MA, Hansen K, Banks WA., (2012). Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier:protection by the antioxidant n-acetylcysteine. Brain Behav Immun 26:1085–94
    • (2012) Brain Behav Immun , vol.26 , pp. 1085-1094
    • Erickson, M.A.1    Hansen, K.2    Banks, W.A.3
  • 8
    • 0037342554 scopus 로고    scopus 로고
    • The antioxidants alpha-lipoic acid and n-acetylcysteine reverse memory impairment and brain oxidative stress in aged samp8 mice
    • Farr SA, Poon HF, Dogrukol-Ak D, et al. (2003). The antioxidants alpha-lipoic acid and n-acetylcysteine reverse memory impairment and brain oxidative stress in aged samp8 mice. J Neurochem 84:1173–83
    • (2003) J Neurochem , vol.84 , pp. 1173-1183
    • Farr, S.A.1    Poon, H.F.2    Dogrukol-Ak, D.3
  • 9
    • 84868475995 scopus 로고    scopus 로고
    • N-acetylcysteine ethyl ester (nacet): a novel lipophilic cell-permeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential
    • Giustarini D, Milzani A, Dalle-Donne I, et al. (2012). N-acetylcysteine ethyl ester (nacet):a novel lipophilic cell-permeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential. Biochem Pharmacol 84:1522–33
    • (2012) Biochem Pharmacol , vol.84 , pp. 1522-1533
    • Giustarini, D.1    Milzani, A.2    Dalle-Donne, I.3
  • 10
    • 0034023927 scopus 로고    scopus 로고
    • Efficacy of oral long-term n-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials
    • Grandjean EM, Berthet P, Ruffmann R, Leuenberger P., (2000). Efficacy of oral long-term n-acetylcysteine in chronic bronchopulmonary disease:a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 22:209–21
    • (2000) Clin Ther , vol.22 , pp. 209-221
    • Grandjean, E.M.1    Berthet, P.2    Ruffmann, R.3    Leuenberger, P.4
  • 11
    • 0035869559 scopus 로고    scopus 로고
    • Determination of reduced, protein-unbound, and total concentrations of n-acetyl-l-cysteine and l-cysteine in rat plasma by postcolumn ligand substitution high-performance liquid chromatography
    • Harada D, Naito S, Kawauchi Y, et al. (2001). Determination of reduced, protein-unbound, and total concentrations of n-acetyl-l-cysteine and l-cysteine in rat plasma by postcolumn ligand substitution high-performance liquid chromatography. Anal Biochem 290:251–9
    • (2001) Anal Biochem , vol.290 , pp. 251-259
    • Harada, D.1    Naito, S.2    Kawauchi, Y.3
  • 12
    • 84872814431 scopus 로고    scopus 로고
    • Amelioration of acute sequelae of blast induced mild traumatic brain injury by n-acetyl cysteine: a double-blind, placebo controlled study
    • Hoffer ME, Balaban C, Slade MD, et al. (2013). Amelioration of acute sequelae of blast induced mild traumatic brain injury by n-acetyl cysteine:a double-blind, placebo controlled study. PLoS One 8:e54163
    • (2013) PLoS One , vol.8 , pp. 54163
    • Hoffer, M.E.1    Balaban, C.2    Slade, M.D.3
  • 13
    • 0014145811 scopus 로고
    • Laboratory and clinical evaluation of the mucolytic properties of acetylcysteine
    • Hurst GA, Shaw PB, LeMaistre CA., (1967). Laboratory and clinical evaluation of the mucolytic properties of acetylcysteine. Am Rev Respir Dis 96:962–70
    • (1967) Am Rev Respir Dis , vol.96 , pp. 962-970
    • Hurst, G.A.1    Shaw, P.B.2    LeMaistre, C.A.3
  • 14
    • 84879415192 scopus 로고    scopus 로고
    • Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position
    • Kalvass JC, Polli JW, Bourdet DL, et al. (2013). Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely:the ITC evidence-based position. Clin Pharmacol Ther 94:80–94
    • (2013) Clin Pharmacol Ther , vol.94 , pp. 80-94
    • Kalvass, J.C.1    Polli, J.W.2    Bourdet, D.L.3
  • 15
    • 0038274495 scopus 로고    scopus 로고
    • Contribution of organic anion transporter 3 (slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier
    • Kikuchi R, Kusuhara H, Sugiyama D, Sugiyama Y., (2003). Contribution of organic anion transporter 3 (slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier. J Pharmacol Exp Ther 306:51–8
    • (2003) J Pharmacol Exp Ther , vol.306 , pp. 51-58
    • Kikuchi, R.1    Kusuhara, H.2    Sugiyama, D.3    Sugiyama, Y.4
  • 16
    • 0036784093 scopus 로고    scopus 로고
    • Identification of a mechanism by which the methylmercury antidotes n-acetylcysteine and dimercaptopropanesulfonate enhance urinary metal excretion: transport by the renal organic anion transporter-1
    • Koh AS, Simmons-Willis TA, Pritchard JB, et al. (2002). Identification of a mechanism by which the methylmercury antidotes n-acetylcysteine and dimercaptopropanesulfonate enhance urinary metal excretion:transport by the renal organic anion transporter-1. Mol Pharmacol 62:921–6
    • (2002) Mol Pharmacol , vol.62 , pp. 921-926
    • Koh, A.S.1    Simmons-Willis, T.A.2    Pritchard, J.B.3
  • 17
    • 12344261030 scopus 로고    scopus 로고
    • Active efflux across the blood-brain barrier: role of the solute carrier family
    • Kusuhara H, Sugiyama Y., (2005). Active efflux across the blood-brain barrier:role of the solute carrier family. NeuroRx 2:73–85
    • (2005) NeuroRx , vol.2 , pp. 73-85
    • Kusuhara, H.1    Sugiyama, Y.2
  • 18
    • 0020325272 scopus 로고
    • Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans
    • Laskin OL, de Miranda P, King DH, et al. (1982). Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother 21:804–7
    • (1982) Antimicrob Agents Chemother , vol.21 , pp. 804-807
    • Laskin, O.L.1    de Miranda, P.2    King, D.H.3
  • 19
    • 22744440362 scopus 로고    scopus 로고
    • Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
    • Löscher W, Potschka H., (2005). Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Progress in Neurobiology 76:22–76
    • (2005) Progress in Neurobiology , vol.76 , pp. 22-76
    • Löscher, W.1    Potschka, H.2
  • 20
    • 84900557627 scopus 로고    scopus 로고
    • Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (oat) 1 and oat3 in humans
    • Maeda K, Tian Y, Fujita T, et al. (2014). Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (oat) 1 and oat3 in humans. Eur J Pharm Sci 59:94–103
    • (2014) Eur J Pharm Sci , vol.59 , pp. 94-103
    • Maeda, K.1    Tian, Y.2    Fujita, T.3
  • 21
    • 84952949019 scopus 로고    scopus 로고
    • Combination therapies for traumatic brain injury: retrospective considerations
    • Margulies S, Anderson G, Atif F, et al. (2016). Combination therapies for traumatic brain injury:retrospective considerations. J Neurotrauma 33:101–12
    • (2016) J Neurotrauma , vol.33 , pp. 101-112
    • Margulies, S.1    Anderson, G.2    Atif, F.3
  • 22
    • 0029154990 scopus 로고
    • Uptake and distribution of n-acetylcysteine in mice: tissue-specific effects on glutathione concentrations
    • McLellan LI, Lewis AD, Hall DJ, et al. (1995). Uptake and distribution of n-acetylcysteine in mice:tissue-specific effects on glutathione concentrations. Carcinogenesis 16:2099–106
    • (1995) Carcinogenesis , vol.16 , pp. 2099-2106
    • McLellan, L.I.1    Lewis, A.D.2    Hall, D.J.3
  • 23
    • 47949121279 scopus 로고    scopus 로고
    • Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats
    • Minematsu T, Hashimoto T, Aoki T, et al. (2008). Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats. Drug Metab Dispos 36:1496–504
    • (2008) Drug Metab Dispos , vol.36 , pp. 1496-1504
    • Minematsu, T.1    Hashimoto, T.2    Aoki, T.3
  • 24
    • 0035503798 scopus 로고    scopus 로고
    • Therapeutic efficacy of aortic administration of n-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model
    • Neuwelt EA, Pagel MA, Hasler BP, et al. (2001). Therapeutic efficacy of aortic administration of n-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 61:7868–74
    • (2001) Cancer Res , vol.61 , pp. 7868-7874
    • Neuwelt, E.A.1    Pagel, M.A.2    Hasler, B.P.3
  • 25
    • 2642579050 scopus 로고    scopus 로고
    • A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis
    • Offen D, Gilgun-Sherki Y, Barhum Y, et al. (2004). A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem 89:1241–51
    • (2004) J Neurochem , vol.89 , pp. 1241-1251
    • Offen, D.1    Gilgun-Sherki, Y.2    Barhum, Y.3
  • 26
    • 0023835113 scopus 로고
    • Pharmacokinetics and bioavailability of reduced and oxidized n-acetylcysteine
    • Olsson B, Johansson M, Gabrielsson J, Bolme P., (1988). Pharmacokinetics and bioavailability of reduced and oxidized n-acetylcysteine. Eur J Clin Pharmacol 34:77–82
    • (1988) Eur J Clin Pharmacol , vol.34 , pp. 77-82
    • Olsson, B.1    Johansson, M.2    Gabrielsson, J.3    Bolme, P.4
  • 27
    • 0034753085 scopus 로고    scopus 로고
    • Mercapturic acids (n-acetylcysteine s-conjugates) as endogenous substrates for the renal organic anion transporter-1
    • Pombrio JM, Giangreco A, Li L, et al. (2001). Mercapturic acids (n-acetylcysteine s-conjugates) as endogenous substrates for the renal organic anion transporter-1. Mol Pharmacol 60:1091–9
    • (2001) Mol Pharmacol , vol.60 , pp. 1091-1099
    • Pombrio, J.M.1    Giangreco, A.2    Li, L.3
  • 28
    • 0018651356 scopus 로고
    • Intravenous n-acetylcystine: the treatment of choice for paracetamol poisoning
    • Prescott LF, Illingworth RN, Critchley JA, et al. (1979). Intravenous n-acetylcystine:the treatment of choice for paracetamol poisoning. Br Med J 2:1097–100
    • (1979) Br Med J , vol.2 , pp. 1097-1100
    • Prescott, L.F.1    Illingworth, R.N.2    Critchley, J.A.3
  • 29
    • 84891883913 scopus 로고    scopus 로고
    • Existing and potential therapeutic uses for n-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits
    • Rushworth GF, Megson IL., (2014). Existing and potential therapeutic uses for n-acetylcysteine:the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther 141:150–9
    • (2014) Pharmacol Ther , vol.141 , pp. 150-159
    • Rushworth, G.F.1    Megson, I.L.2
  • 30
    • 84877828545 scopus 로고    scopus 로고
    • The chemistry and biological activities of n-acetylcysteine
    • Samuni Y, Goldstein S, Dean OM, Berk M., (2013). The chemistry and biological activities of n-acetylcysteine. Biochim Biophys Acta 1830:4117–29
    • (2013) Biochim Biophys Acta , vol.1830 , pp. 4117-4129
    • Samuni, Y.1    Goldstein, S.2    Dean, O.M.3    Berk, M.4
  • 31
    • 0024991044 scopus 로고
    • Modeling the enhanced uptake of zidovudine (azt) into cerebrospinal fluid. 1. Effect of probenecid
    • Sawchuk RJ, Hedaya MA., (1990). Modeling the enhanced uptake of zidovudine (azt) into cerebrospinal fluid. 1. Effect of probenecid. Pharm Res 7:332–8
    • (1990) Pharm Res , vol.7 , pp. 332-338
    • Sawchuk, R.J.1    Hedaya, M.A.2
  • 32
    • 24944482460 scopus 로고    scopus 로고
    • Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans
    • Shimizu M, Fuse K, Okudaira K, et al. (2005). Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metabo Dispos 33:1477–81
    • (2005) Drug Metabo Dispos , vol.33 , pp. 1477-1481
    • Shimizu, M.1    Fuse, K.2    Okudaira, K.3
  • 33
    • 84868661468 scopus 로고    scopus 로고
    • Role of the blood-cerebrospinal fluid barrier transporter as a cerebral clearance system for prostaglandin e(2) produced in the brain
    • Tachikawa M, Ozeki G, Higuchi T, et al. (2012). Role of the blood-cerebrospinal fluid barrier transporter as a cerebral clearance system for prostaglandin e(2) produced in the brain. J Neurochem 123:750–60
    • (2012) J Neurochem , vol.123 , pp. 750-760
    • Tachikawa, M.1    Ozeki, G.2    Higuchi, T.3
  • 34
    • 33645798634 scopus 로고    scopus 로고
    • Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid
    • Tahara H, Kusuhara H, Maeda K, et al. (2006). Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos 34:743–7
    • (2006) . Drug Metab Dispos , vol.34 , pp. 743-747
    • Tahara, H.1    Kusuhara, H.2    Maeda, K.3
  • 35
    • 0029642277 scopus 로고
    • On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP)
    • Versantvoort CHM, Bagrij T, Wright KA, Twentyman PR., (1995). On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP). Int J Cancer 63:855–62
    • (1995) Int J Cancer , vol.63 , pp. 855-862
    • Versantvoort, C.H.M.1    Bagrij, T.2    Wright, K.A.3    Twentyman, P.R.4
  • 36
    • 0027769788 scopus 로고
    • Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis
    • Wong SL, Van Belle K, Sawchuk RJ., (1993). Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit:investigation of the inhibitory effect of probenecid utilizing microdialysis. J Pharmacol Exp Ther 264:899–909
    • (1993) J Pharmacol Exp Ther , vol.264 , pp. 899-909
    • Wong, S.L.1    Van Belle, K.2    Sawchuk, R.J.3
  • 37
    • 84947044454 scopus 로고    scopus 로고
    • Intravenous administration of stable-labeled n-acetylcysteine demonstrates an indirect mechanism for boosting glutathione and improving redox status
    • Zhou J, Coles LD, Kartha RV, et al. (2015). Intravenous administration of stable-labeled n-acetylcysteine demonstrates an indirect mechanism for boosting glutathione and improving redox status. J Pharm Sci 104:2619–26
    • (2015) J Pharm Sci , vol.104 , pp. 2619-2626
    • Zhou, J.1    Coles, L.D.2    Kartha, R.V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.